Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | AANAT | Q16613 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | MC5R | P33032 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258567 | 0.92 | IDO1 (0.57) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL2799585 | 0.89 | MEN1 (0.65) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL21562558 | 0.86 | KMT2A (0.53) | MEN1KMT2ALMNACYP1A2PKM | |
| SCHEMBL20258565 | 0.83 | SPR (0.62) | MEN1KMT2ALMNACYP1A2TSHR | |
| SCHEMBL21562515 | 0.83 | HTR2A (0.57) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL20258534 | 0.82 | MTNR1A (0.64) | MEN1KMT2ACYP1A2BLMNPC1 | |
| SCHEMBL21562513 | 0.82 | MTNR1A (0.50) | MEN1KMT2ALMNATSHRMMP9 | |
| SCHEMBL20258635 | 0.82 | MTNR1A (0.62) | LMNATSHRMMP9HTR2ASMN1; SMN2 | |
| SCHEMBL20258597 | 0.82 | NOTUM (0.70) | KMT2AHTR1AHTR2A | |
| SCHEMBL20258624 | 0.82 | HTR6 (0.56) | MEN1KMT2ALMNACYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20190345103-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018106907-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY | NOVATARG, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | MEN1 3290/4885KMT2A 3151/4885LMNA 4393/4885 |
| US-20190345103-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | MEN1 3290/4885KMT2A 3151/4885LMNA 4393/4885 |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | MEN1 3290/4885KMT2A 3151/4885LMNA 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.